NASDAQ:PTIX Atrinsic (PTIX) Stock Price, News & Analysis $0.75 0.00 (0.00%) As of 10/16/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsSEC Filings About Atrinsic Stock (NASDAQ:PTIX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Atrinsic alerts:Sign Up Key Stats Today's Range$0.75▼$0.7550-Day Range$0.32▼$1.2052-Week Range$0.13▼$3.32Volume11 shsAverage Volume27,332 shsMarket Capitalization$1.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Atrinsic, Inc. was a digital marketing and online advertising company that operated during the 2000s and early 2010s. Its business focused on customer acquisition, performance-based marketing and direct-response campaigns conducted through online channels. The company used websites, email marketing, search marketing and other digital media to promote products and services for advertisers and merchants. Its activities were primarily directed at internet users in the United States, although online marketing programs could reach consumers in other markets. Atrinsic is no longer the operating name associated with the company. Following a corporate transaction, the business was renamed Protagenic Therapeutics, Inc., which subsequently pursued biotechnology research and development rather than Atrinsic’s former digital marketing activities.AI Generated. May Contain Errors. Read More Atrinsic Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks1st Percentile Overall ScorePTIX MarketRank™: 0.025112344695 of 5 starsAtrinsic scored higher than 1% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingAtrinsic has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageAtrinsic has received no research coverage in the past 90 days.Read more about Atrinsic's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Atrinsic is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atrinsic is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtrinsic has a P/B Ratio of 0.38. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Atrinsic's valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PTIX. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAtrinsic does not currently pay a dividend.Dividend GrowthAtrinsic does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Atrinsic this week, compared to 0 articles on an average week. Company Ownership0.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Atrinsic insiders have not sold or bought any company stock.Percentage Held by Insiders8.00% of the stock of Atrinsic is held by insiders.Percentage Held by Institutions7.97% of the stock of Atrinsic is held by institutions.Read more about Atrinsic's insider trading history. Receive PTIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atrinsic and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTIX Stock News HeadlinesAtrinsic (NASDAQ:PTIX) Stock Price Down 6.3% - Here's WhyOctober 16 at 2:01 AM | americanbankingnews.comProtagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug CandidatesJuly 30, 2025 | globenewswire.comBuy These Five AI Plays Before October 20Jeff Brown, founder and CEO of Brownstone Research, says a new market cycle he calls the million dollar cycle is set to begin by October 20. Brown has built a new model portfolio featuring five AI plays tied to this pattern, which he says has repeated with a track record of success in the past. He notes this cycle unfolds outside the traditional stock market, combined with the ongoing AI boom.October 18 at 1:00 AM | Brownstone Research (Ad)Protagenic Therapeutics, Inc. (PTIX) - Yahoo FinanceJune 24, 2025 | finance.yahoo.comProtagenic & Phytanix Merge in All-Stock Move, Sparking Retail FrenzyMay 29, 2025 | msn.comProtagenic Therapeutics swaps warrants for sharesMay 21, 2025 | uk.investing.comProtagenic Therapeutics Shares Double After Buyout Offer From Phytanix BioMay 20, 2025 | marketwatch.comProtagenic Therapeutics stock soars on merger to create Neuroactive Biopharmaceutical companyMay 20, 2025 | in.investing.comSee More Headlines PTIX Stock Analysis - Frequently Asked Questions How have PTIX shares performed this year? Atrinsic's stock was trading at $1.30 at the beginning of the year. Since then, PTIX shares have decreased by 42.3% and is now trading at $0.75. How were Atrinsic's earnings last quarter? Atrinsic Inc. (NASDAQ:PTIX) issued its earnings results on Wednesday, September, 10th. The company reported ($1.37) earnings per share (EPS) for the quarter. When did Atrinsic's stock split? Atrinsic's stock reverse split before market open on Monday, May 5th 2025.A 1-14 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Sunday, May 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. How do I buy shares of Atrinsic? Shares of PTIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Atrinsic own? Based on aggregate information from My MarketBeat watchlists, some other companies that Atrinsic investors own include Aptorum Group (APM), Plug Power (PLUG), Boeing (BA), Bank of America (BAC), Astrotech (ASTC), Athersys (ATHX) and American Airlines Group (AAL). Company Calendar Last Earnings9/10/2025Today10/18/2026Next Earnings (Estimated)11/17/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (11m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PTIX's financial health is in the Red zone, according to TradeSmith. PTIX has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PTIX CIK1022899 Webphytanix.com Phone212-994-8200Fax603-761-6223Employees2Year Founded1994Profitability EPS (Trailing Twelve Months)$2.23 Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.53 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-379.72% Debt Debt-to-Equity RatioN/A Current Ratio0.29 Quick Ratio0.29 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.96 per share Price / Book0.38Miscellaneous Outstanding Shares1,810,000Free Float1,780,000Market Cap$1.36 million OptionableNot Optionable Beta1.84 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:PTIX) was last updated on 10/16/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredThey're not buying gold. They're buying this.Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThis high yielding “gold annuity” is starting to move…Garrett Goggin, a 20+ year gold analyst, has called major moves before: Montage Gold up 2,567%, G2 Goldfields ...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atrinsic Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atrinsic With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
